Login to Your Account

Treos readies jump into phase I cancer vaccine trial

By Michael Fitzhugh
Staff Writer

Thursday, September 21, 2017

Treos Bio Ltd., a London-based company developing precision peptide cancer vaccines coupled with companion diagnostics, has enlisted Pharmaceutical Product Development LLC to manage a phase I trial of PolyPEPI-1018, its lead vaccine for colorectal cancer. Once an investigational new drug application the company is filing is accepted, the trial is expected to start by late January 2018.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription